TeamDrive
RUS

Russian State Duma to ease imports of APIs

11 January 2018

Remedium

The Russian national Parliament (State Duma) plans to approve a bill that will ease imports of active pharmaceutical ingredients (APIs) to the country, according to press-service of the Russian Duma, reports The Pharma Letter’s local correspondent.

Under the current Russian legislation, the country’s state register of drugs usually contains information about an active substance of the drug, instead of a finished product. Therefore drug imports to Russia are usually associated with the need to conduct several examinations of these products. The first of them involves checking the quality of the substance in the composition of the drug, while the second one checking an actual presence of an active substance.

A spokesman of the Russian State Duma said the new state initiative could be beneficial for domestic drugmakers, as it will provide significant savings for them, both in terms of finance and timing. According to him, the existence of such checks significantly slows down and increases the cost of import substitution for the Russian pharmaceutical industry. This leads to discrimination against domestic producers, and significantly increases the time and cost of finished products.

At the same time, such requirements do not apply to foreign manufacturers, which are only required to register a finished product in the state register.

In this regard, the State Duma proposes to determine that an active pharmaceutical ingredient is considered included in the state register of drugs since the inclusion of a drug (in which composition it included) into it. Such a rule is proposed to extend to the purchases, imports and any other use of such substances.

Source


Previous publication Next publication

Media Center

  • 18 January 2018

    Russian President signs the Federal Law on introduction of drug labeling

    Russian President Vladimir Putin signed the Federal Law “On amendments to the Federal law “On Circulation of medicines.” The law provides for the establishment of state information system to monitor the movement of medicinal products for human use from the manufacturer to the final consumer by using the means of identification with regard to medicinal products in order to ensure the quality control of medicinal products for human use, that are in circulation, and protect the legal trade from falsified, counterfeit, and substandard medicines.

  • 18 January 2018

    Russia has one of the shortest periods for expert examination of medicines

    Elena Maksimkina, the Director of the Department of Drug Supply and Regulation of Medical Devices at the Russian Ministry of Health, gave her assessment of the pharmaceutical market in Russia.

  • 17 January 2018

    New tools for turning genes into drug factories

    Synthetic biologists have long dreamed of designing genetic circuits in the body that can produce drugs in response to environmental cues. But it’s been a challenging task. Now scientists at Rice University say they’ve created a toolkit of gene “promoters” that can turn genes on and off at command.

  • 17 January 2018

    FDA approves first treatment for breast cancer with a certain inherited genetic mutation

    The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.

Read more